Spectrum Pharmaceuticals, Inc.

NasdaqCM:SPPI Rapporto sulle azioni

Cap. di mercato: US$209.9m

Spectrum Pharmaceuticals Gestione

Gestione criteri di controllo 1/4

Spectrum Pharmaceuticals Il CEO è Tom Riga, nominato in Dec2021, e ha un mandato di 1.67 anni. la retribuzione annua totale è $ 2.60M, composta da 25% di stipendio e 75% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.26% delle azioni della società, per un valore di $ 537.60K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 2.5 anni.

Informazioni chiave

Tom Riga

Amministratore delegato

US$2.6m

Compenso totale

Percentuale dello stipendio del CEO25.0%
Mandato del CEO1.7yrs
Proprietà del CEO0.3%
Durata media del management1.5yrs
Durata media del Consiglio di amministrazione2.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16
Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04
Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05
Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Aug 12

Spectrum's Big Approval: Any Day Now

Jul 29

FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS

Jun 01

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31
Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12
We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21
Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tom Riga rispetto agli utili di Spectrum Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$650k

-US$78m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$117m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$4mUS$550k

-US$158m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$184m

Mar 31 2021n/an/a

-US$166m

Dec 31 2020US$3mUS$550k

-US$171m

Sep 30 2020n/an/a

-US$162m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$4mUS$550k

-US$135m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$191m

Mar 31 2019n/an/a

-US$147m

Dec 31 2018US$5mUS$500k

-US$127m

Sep 30 2018n/an/a

-US$102m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$1mUS$420k

-US$101m

Compensazione vs Mercato: La retribuzione totale di Tom ($USD 2.60M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.48M ).

Compensazione vs guadagni: La retribuzione di Tom è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Tom Riga (48 yo)

1.7yrs

Mandato

US$2,595,633

Compensazione

Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Thomas Riga
President1.7yrsUS$2.60m0.26%
$ 537.6k
Nora Brennan
Executive VP & CFO1.3yrsUS$46.25k0.051%
$ 108.0k
Keith McGahan
Executive VP5.5yrsUS$1.50m0.11%
$ 239.2k
Michael Grabow
Executive VP & Chief Business Officerless than a yearNessun datoNessun dato

1.5yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di SPPI non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Thomas Riga
President1.7yrsUS$2.60m0.26%
$ 537.6k
Seth H. Fischer
Independent Director3.3yrsUS$178.83k0.0020%
$ 4.2k
William Ashton
Independent Chairman of the Board5.5yrsUS$202.58k0.021%
$ 43.9k
Jeffrey Vacirca
Independent Director4.8yrsUS$181.33k0.13%
$ 278.4k
Brittany Bradrick
Independent Director1.3yrsUS$158.53kNessun dato
Juhyun Lim
Director1.4yrsUS$183.93k0.0023%
$ 4.9k

2.5yrs

Durata media

53.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di SPPI non è considerato esperto (durata media del mandato 2.5 anni), il che suggerisce un nuovo consiglio.